Obesity Featured Articles

  1. What Sponsors Don't See: The Systems Behind Clinical Trial Delivery 6/22/2026

    What do sponsors need from sites? Easy. How do they evaluate them? Not so easy (or accurate). In this column, Association Multisite Research Corporations (AMRC) Executive Director Jim Kremidas explains how sites and sponsors can make site evaluations better.

  2. "We'll Figure It Out Later" Is Where Trial Friction Begins 6/19/2026

    Delayed operational decisions around travel, payments, site workflows, meetings, and compliance can create avoidable friction for sites, participants, sponsors, and CROs once a study is underway.

  3. What Really Happens At The Site When Sponsors Pull Back Mid-Trial 6/19/2026

    When sponsors slow or reduce operational spending due to financial pressure, strategic pivots, or internal restructuring, sites — and patients — suffer. Curo Research CCO Amy Bland explains how sponsors can better manage operational changes.

  4. Where Are We With Clinical Trial Tokenization? 6/19/2026

    In January 2024, I interviewed Tom Dougherty about a topic many clinical research professionals had heard mentioned but few could confidently explain: tokenization. I wanted to get caught up on any progress that has been made, so I completed this Q&A with Dougherty, who is Real-World Data Strategy Director, CMR - Clinical Data Science & Evidence at Novo Nordisk.

  5. The Role Of Oncology Biomarkers In Personalizing Hematology Treatment Plans 6/18/2026

    Oncology biomarkers guide personalized treatment and help track disease changes. Learn more about how advancements like liquid biopsies improve precision care.

  6. Making Informed Decisions In Your Oncology Study: Understanding Biomarkers 6/18/2026

    Oncology biomarkers track tumor burden and reduce radiation from imaging. Composite algorithms improve response prediction. Fit-for-purpose strategies are needed to manage logistics and costs.

  7. Navigating The New Landscape Of Oncology Clinical Trials: A Strategic Imperative For Operations Teams 6/18/2026

    The oncology landscape is growing but faces high screen-fail rates and trial complexity. To succeed, teams must move past traditional playbooks and adopt centralized pre-screening pipelines.

  8. A Sponsor Playbook For Matching AI Use Cases To Readiness, Risk, And ROI 6/18/2026

    Clinical technology consultant Karen Maduschke explains why your next AI investment should solve a problem you can articulate, with data you can access, in a process you can change.

  9. One Drug, Three Indications: How Small ClinOps Teams Manage Multi-Trial Execution 6/17/2026

    Having the same number of clinical programs as team members might sound crazy, but for Step Pharma, it has become one of their biggest strengths.

  10. Rare Disease Nonprofits: De-Risk Development With Orphan Drug Designation And Early Talks With The FDA 6/17/2026

    For nonprofit organizations, Orphan Drug Designation is the start of a disciplined, forward-looking regulatory strategy, but it's not the only factor in success. H. Greg Thomas, Ph.D., shares his advice for de-risking orphan drug development.